Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo

被引:43
|
作者
Schwock, Joerg [2 ]
Pham, Nhu-An [1 ]
Cao, Mary P. [1 ]
Hedley, David W. [1 ,2 ]
机构
[1] Univ Toronto, Ontario Canc Inst, Princess Margaret Hosp, Div Appl Mol Oncol,Dept Med Biophys, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada
基金
加拿大健康研究院;
关键词
Hsp90; geldanamycin; ansamycin; pharmacodynamics; xenograft;
D O I
10.1007/s00280-007-0522-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Heat shock protein 90 (Hsp90) is a conserved chaperone involved in crucial signaling events in normal and malignant cells. Previous research suggests that tumor cells are particularly dependent on Hsp90 for survival as well as malignant progression. Hsp90 inhibitors which are derivates of the natural compound geldanamycin, such as the orally bioavailable 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), are currently being tested in clinical trials and small molecule inhibitors are in development. In this study we investigated the response of a panel of cervical carcinoma cell lines in vitro and in vivo to determine potential factors that might influence the sensitivity towards Hsp90 inhibition. Methods Cell viability, proliferation and drug-induced changes on Hsp90 chaperoned "client" factors were examined with focus on G2/M cell cycle regulators, and a comparison with immortalized and normal keratinocytes was performed. ME180 and CaSki cells were grown as subcutaneous xenografts in mice treated with 6-10 mg/kg 17-DMAG by oral gavage 2x/day on a chronic schedule. Tissue concentrations of 17- DMAG were measured by high performance liquid chromatography. Results Cell death during abnormal mitosis was observed within 48 h after treatment start. ME180 and CaSki showed more cell death at this time point than SiHa and HeLa, and higher levels of pre-treatment Akt activity. IC50 values ranged between 17 and 37 nanoM geldanamycin (MTS). Keratinocytes were at least as sensitive as carcinoma cells. All cell lines responded with an increase of the G2/M fraction. Despite in vitro effectiveness and tissue concentrations of 1 mu M, only a limited tumor growth reduction was observed with 17- DMAG given close to the maximum tolerated dose level. Lower levels of Hsp90 protein, a lower Akt activity and signs of tissue hypoxia were observed in xenografts compared to cell cultures. Conclusions We show here that Hsp90 inhibition effectively induces apoptosis and growth arrest in cervical carcinoma cells in vitro. Mitotic catastrophe was identified as one mechanism of cell death. In contrast, a limited efficacy of 17- DMAG was observed in subcutaneous xenograft models. Induction of a heat shock response has previously been implicated in resistance towards Hsp90 inhibition. Additional factors might be (1) an altered abundance and/or activity of primary (Hsp90) and secondary (e. g., Akt) target(s), (2) a narrow therapeutic range of 17- DMAG by oral application and (3) response-modifying factors within the tumor environment. The further development of synthetic Hsp90 inhibitors with increased therapeutic window is warranted.
引用
收藏
页码:669 / 681
页数:13
相关论文
共 50 条
  • [1] Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo
    Jörg Schwock
    Nhu-An Pham
    Mary P. Cao
    David W. Hedley
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 669 - 681
  • [2] SENSITIZATION OF HUMAN OSTEOSARCOMA CELLS TO HSP90 INHIBITION BY TELOMERASE INHIBITION IN VITRO AND IN VIVO
    Dome, J.
    Bobb, D.
    He, J.
    Gryaznov, S.
    McCarter, R.
    Hu, Y.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 155 - 155
  • [3] Differential effects of Hsp90 inhibition on corneal cells in vitro and in vivo
    Raghunathan, VijayKrishna
    Edwards, Sydney Garrison
    Leonard, Brian C.
    Kim, Soohyun
    Evashenk, Alexander T.
    Song, Yeonju
    Rewinski, Eva
    Price, Ariana Marangakis
    Hoehn, Alyssa
    Chang, Connor
    Reilly, Christopher M.
    Muppala, Santoshi
    Murphy, Christopher J.
    Thomasy, Sara M.
    EXPERIMENTAL EYE RESEARCH, 2021, 202
  • [4] Increased radiosensitization in cervical tumor cells following HSP90 inhibition with geldanamycin
    Gius, D
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S106 - S106
  • [5] HSP90 inhibition in angiosarcoma
    Spiegelberg, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (02) : 343 - 344
  • [6] Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors
    Kang, Junghee
    Kamal, Adeela
    Burrows, Francis J.
    Evers, B. Mark
    Chung, Dai H.
    ANTICANCER RESEARCH, 2006, 26 (3A) : 1903 - 1908
  • [7] Inhibition of Hsp90 sensitizes pancreatic cancer in vitro and in vivo to chemo-radiotherapy
    Nagaraju, Ganji Purnachandra
    El-Rayes, Bassel F.
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Effect of inhibition of the Ubiquitin-Proteasome System and Hsp90 on growth and survival of Rhabdomyosarcoma cells in vitro
    Marica Peron
    Paolo Bonvini
    Angelo Rosolen
    BMC Cancer, 12
  • [9] Effect of inhibition of the Ubiquitin-Proteasome System and Hsp90 on growth and survival of Rhabdomyosarcoma cells in vitro
    Peron, Marica
    Bonvini, Paolo
    Rosolen, Angelo
    BMC CANCER, 2012, 12
  • [10] Hsp90 inhibition sensitizes DLBCL cells to cisplatin
    Schmidt, Linnea
    Issa, Issa Ismail
    Haraldsdottir, Hulda
    Hald, Jonas Laugard
    Schmitz, Alexander
    Due, Hanne
    Dybkaer, Karen
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (04) : 431 - 440